{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:51Z","timestamp":1793831331041,"version":"4.6.1"},"reference-count":146,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021856","name":"Ministero dell'Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2022PKWF9"],"award-info":[{"award-number":["2022PKWF9"]}],"id":[{"id":"10.13039\/501100021856","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.autrev.2024.103514","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:13:22Z","timestamp":1704327202000},"page":"103514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity"],"prefix":"10.1016","volume":"23","author":[{"given":"Elvira","family":"Favoino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Liakouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Sisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Navarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vomero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ciccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruscitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Racanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.autrev.2024.103514_bb0005","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01915-2018","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"53","author":"Kim","year":"2019","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0015","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrcardio.2017.84","article-title":"Epidemiology and treatment of pulmonary arterial hypertension","volume":"14","author":"Lau","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1164\/rccm.200806-953OC","article-title":"Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era","volume":"179","author":"Condliffe","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0025","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.10-0260","article-title":"Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype","volume":"138","author":"Chung","year":"2010","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0030","first-page":"267","article-title":"Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature","volume":"32","author":"Prete","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0035","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1164\/rccm.201507-1456OC","article-title":"Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension","volume":"192","author":"Rhee","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"25 Suppl","key":"10.1016\/j.autrev.2024.103514_bb0040","doi-asserted-by":"crossref","first-page":"D51","DOI":"10.1016\/j.jacc.2013.10.023","article-title":"Pulmonary arterial hypertension: epidemiology and registries","volume":"62","author":"McGoon","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0045","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1183\/09031936.00094112","article-title":"Survivor bias and risk assessment","volume":"40","author":"Miller","year":"2012","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0050","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1183\/09031936.00196611","article-title":"Predicting survival in pulmonary arterial hypertension in the UK","volume":"40","author":"Lee","year":"2012","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0055","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.autrev.2024.103514_bb0065","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0025-6196(11)60769-6","article-title":"Design of the REVEAL registry for US patients with pulmonary arterial hypertension","volume":"83","author":"McGoon","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0070","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1183\/09031936.00057010","article-title":"Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension","volume":"36","author":"Humbert","year":"2010","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0080","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1378\/chest.10-0075","article-title":"The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US contemporary registries","volume":"139","author":"Frost","year":"2011","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0085","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1183\/09031936.00101211","article-title":"Survival in pulmonary hypertension in Spain: insights from the Spanish registry","volume":"40","author":"Escribano-Subias","year":"2012","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.autrev.2024.103514_bb0090","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0095","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ijcard.2012.10.026","article-title":"Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: results from the COMPERA registry","volume":"168","author":"Hoeper","year":"2013","journal-title":"Int J Cardiol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0100","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","article-title":"An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry","volume":"142","author":"Benza","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0105","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982-2006","volume":"30","author":"Thenappan","year":"2007","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0110","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4103\/2045-8932.101655","article-title":"The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension","volume":"2","author":"Zeng","year":"2012","journal-title":"Pulm Circ"},{"issue":"12 Suppl S","key":"10.1016\/j.autrev.2024.103514_bb0115","doi-asserted-by":"crossref","first-page":"25S","DOI":"10.1016\/j.jacc.2004.02.033","article-title":"Pathologic assessment of vasculopathies in pulmonary hypertension","volume":"43","author":"Pietra","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0120","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.healun.2009.07.005","article-title":"Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension","volume":"29","author":"Chandra","year":"2010","journal-title":"J Heart Lung Transplant"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.semarthrit.2014.03.002","article-title":"Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS) cohort study","volume":"44","author":"Hsu","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0130","first-page":"1956","article-title":"Novel biomarker for pulmonary vascular disease in systemic sclerosis patients","volume":"40","author":"Favoino","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0140","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccm.2013.08.009","article-title":"Pathology of pulmonary hypertension","volume":"34","author":"Tuder","year":"2013","journal-title":"Clin Chest Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0145","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.humpath.2006.11.022","article-title":"Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases","volume":"38","author":"Dorfm\u00fcller","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.autrev.2024.103514_bb0150","article-title":"Pulmonary hypertension: linking inflammation and pulmonary arterial stiffening","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065085","article-title":"Systemic lupus erythematosus and pulmonary hypertension","volume":"24","author":"Parperis","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0160","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1183\/09031936.00106008","article-title":"Pulmonary arterial hypertension in limited cutaneous systemic sclerosis: a distinctive vasculopathy","volume":"34","author":"Overbeek","year":"2009","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0165","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2559.2012.04246.x","article-title":"Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension","volume":"61","author":"Pogoriler","year":"2012","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0170","first-page":"389","article-title":"Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension","volume":"146","author":"Chazova","year":"1995","journal-title":"Am J Pathol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0175","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jmg.37.10.741","article-title":"Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family","volume":"37","author":"Thomson","year":"2000","journal-title":"J Med Genet"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0180","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension","volume":"26","author":"Lane","year":"2000","journal-title":"Nat Genet"},{"issue":"17","key":"10.1016\/j.autrev.2024.103514_bb0185","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1161\/01.CIR.0000033830.36431.46","article-title":"Stimulation of Id1 expression by bone morphogenetic protein is sufficient and necessary for bone morphogenetic protein-induced activation of endothelial cells","volume":"106","author":"Valdimarsdottir","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1161\/01.RES.0000200180.01710.e6","article-title":"Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension","volume":"98","author":"Teichert-Kuliszewska","year":"2006","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100261","article-title":"Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension","volume":"9","author":"Pousada","year":"2014","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0200","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-2600(15)00544-5","article-title":"BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis","volume":"4","author":"Evans","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.autrev.2024.103514_bb0205","doi-asserted-by":"crossref","first-page":"33570","DOI":"10.1038\/srep33570","article-title":"Complex inheritance in pulmonary arterial hypertension patients with several mutations","volume":"6","author":"Pousada","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13073-019-0685-z","article-title":"Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension","volume":"11","author":"Zhu","year":"2019","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0215","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/14728222.2017.1275567","article-title":"Restoring BMPRII functions in pulmonary arterial hypertension: opportunities, challenges and limitations","volume":"21","author":"Guignabert","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"21","key":"10.1016\/j.autrev.2024.103514_bb0220","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1161\/CIRCULATIONAHA.114.008777","article-title":"Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension","volume":"129","author":"Lavoie","year":"2014","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0225","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/jcmm.12105","article-title":"Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma","volume":"17","author":"Wang","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0230","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1164\/rccm.201408-1464OC","article-title":"Impaired bone morphogenetic protein receptor II signaling in a transforming growth factor-\u00ce2-dependent mouse model of pulmonary hypertension and in systemic sclerosis","volume":"191","author":"Gilbane","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.autrev.2024.103514_bb0235","article-title":"E2F1 mediates SOX17 deficiency-induced pulmonary hypertension","author":"Yi","year":"2023","journal-title":"bioRxiv"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0240","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.118.002087","article-title":"Loss-of-function ABCC8 mutations in pulmonary arterial hypertension","volume":"11","author":"Bohnen","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0245","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01609-2018","article-title":"Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension","volume":"53","author":"Wang","year":"2019","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/cells10061488","article-title":"Novel genetic and molecular pathways in pulmonary arterial hypertension associated with connective tissue disease","volume":"10","author":"Hernandez-Gonzalez","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0255","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13073-021-00891-1","article-title":"Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH","volume":"13","author":"Zhu","year":"2021","journal-title":"Genome Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12931-022-01987-x","article-title":"Gene panel diagnostics reveals new pathogenic variants in pulmonary arterial hypertension","volume":"23","author":"Eichstaedt","year":"2022","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0265","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cardiores.2003.11.026","article-title":"The endothelin system in pulmonary arterial hypertension","volume":"61","author":"Gali\u00e9","year":"2004","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0270","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamacardio.2016.0962","article-title":"Association of Elevated Plasma Endothelin-1 levels with pulmonary hypertension, mortality, and heart failure in African American individuals: the Jackson heart study","volume":"1","author":"Jankowich","year":"2016","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0275","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10067-013-2354-8","article-title":"Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis","volume":"33","author":"Ciurzynski","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0280","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00296-008-0829-8","article-title":"Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis","volume":"29","author":"Coral-Alvarado","year":"2009","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0285","first-page":"14","article-title":"Nitric oxide and pulmonary arterial hypertension","volume":"2017","author":"Chester","year":"2017","journal-title":"Glob Cardiol Sci Pract"},{"issue":"5","key":"10.1016\/j.autrev.2024.103514_bb0290","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/13993003.00245-2016","article-title":"Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension","volume":"48","author":"Zhang","year":"2016","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.autrev.2024.103514_bb0295","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1161\/01.ATV.0000168414.06853.f0","article-title":"Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension","volume":"25","author":"Kielstein","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103514_bb0300","first-page":"129","article-title":"The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: a case control study","volume":"34 Suppl 100","author":"Thakkar","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2024.103514_bb0305","doi-asserted-by":"crossref","first-page":"3741909","DOI":"10.1155\/2019\/3741909","article-title":"Clinical value of asymmetrical Dimethylarginine detection in patients with connective tissue disease-associated pulmonary arterial hypertension","volume":"2019","author":"Liu","year":"2019","journal-title":"Cardiol Res Pract"},{"issue":"11","key":"10.1016\/j.autrev.2024.103514_bb0310","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/rheumatology\/ken346","article-title":"Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension","volume":"47","author":"Dimitroulas","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0315","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0163-7827(03)00037-7","article-title":"Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway","volume":"43","author":"Murakami","year":"2004","journal-title":"Prog Lipid Res"},{"issue":"17","key":"10.1016\/j.autrev.2024.103514_bb0320","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1161\/01.CIR.0000145613.01188.0B","article-title":"Intravascular thrombosis after hypoxia-induced pulmonary hypertension: regulation by cyclooxygenase-2","volume":"110","author":"Pidgeon","year":"2004","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0325","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM199207093270202","article-title":"An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension","volume":"327","author":"Christman","year":"1992","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0330","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1164\/ajrccm.159.6.9804054","article-title":"Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension","volume":"159","author":"Tuder","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041264","article-title":"Molecular pharmacology of VEGF-A isoforms: binding and Signalling at VEGFR2","volume":"19","author":"Peach","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0340","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1183\/09031936.00174908","article-title":"Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension","volume":"34","author":"Selimovic","year":"2009","journal-title":"Eur Respir J"},{"issue":"18","key":"10.1016\/j.autrev.2024.103514_bb0345","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1093\/eurheartj\/ehq226","article-title":"Circulating angiopoietins in idiopathic pulmonary arterial hypertension","volume":"31","author":"K\u00fcmpers","year":"2010","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0350","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/03009742.2017.1378714","article-title":"Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension","volume":"47","author":"Kylhammar","year":"2018","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0355","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00037-2019","article-title":"Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation","volume":"5","author":"S\u00e4leby","year":"2019","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.autrev.2024.103514_bb0360","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2466-9-18","article-title":"Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis","volume":"9","author":"Papaioannou","year":"2009","journal-title":"BMC Pulm Med"},{"issue":"8","key":"10.1016\/j.autrev.2024.103514_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012106","article-title":"Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury","volume":"5","author":"Pendergrass","year":"2010","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0370","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1253\/circrep.CR-20-0096","article-title":"Endostatin and vascular endothelial growth factor-a(165)b may contribute to classification of pulmonary hypertension","volume":"3","author":"Adachi","year":"2021","journal-title":"Circ Rep"},{"key":"10.1016\/j.autrev.2024.103514_bb0375","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ijcard.2016.07.277","article-title":"Association between levels of anti-angiogenic isoform of vascular endothelial growth factor a and pulmonary hypertension","volume":"222","author":"Suzuki","year":"2016","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0380","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13075-015-0712-4","article-title":"Biomarkers of pulmonary hypertension in patients with scleroderma: a case-control study","volume":"17","author":"McMahan","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.autrev.2024.103514_bb0385","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1183\/13993003.00187-2015","article-title":"New potential diagnostic biomarkers for pulmonary hypertension","volume":"46","author":"Tiede","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0390","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4103\/2045-8932.110445","article-title":"Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension","volume":"3","author":"Malhotra","year":"2013","journal-title":"Pulm Circ"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0395","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1046\/j.1440-1827.2000.01068.x","article-title":"Expression of vascular endothelial growth factor and its receptors correlates closely with formation of the plexiform lesion in human pulmonary hypertension","volume":"50","author":"Hirose","year":"2000","journal-title":"Pathol Int"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0400","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.953","article-title":"Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis","volume":"195","author":"Tuder","year":"2001","journal-title":"J Pathol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0405","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.autrev.2011.04.019","article-title":"Angiogenic cytokines and growth factors in systemic sclerosis","volume":"10","author":"Liakouli","year":"2011","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0410","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1183\/09031936.00044911","article-title":"A role for the CXCL12 receptor, CXCR7, in the pathogenesis of human pulmonary vascular disease","volume":"39","author":"Costello","year":"2012","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0415","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0002-9440(10)65365-5","article-title":"Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: in vivo neovascularization induced by stromal-derived factor-1alpha","volume":"154","author":"Salcedo","year":"1999","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0420","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0049-3848(00)00292-9","article-title":"SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models","volume":"99","author":"Mirshahi","year":"2000","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0425","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.bbrc.2007.05.182","article-title":"CXCR4\/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway","volume":"359","author":"Liang","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0430","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s13238-011-1097-z","article-title":"SDF-1\/CXCR4 axis modulates bone marrow mesenchymal stem cell apoptosis, migration and cytokine secretion","volume":"2","author":"Liu","year":"2011","journal-title":"Protein Cell"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123709","article-title":"Elevated plasma CXCL12\u03b1 is associated with a poorer prognosis in pulmonary arterial hypertension","volume":"10","author":"McCullagh","year":"2015","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0440","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4103\/2045-8932.83448","article-title":"Hypoxic pulmonary hypertension in mice with constitutively active platelet-derived growth factor receptor-\u00ce2","volume":"1","author":"Dahal","year":"2011","journal-title":"Pulm Circ"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0445","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1002\/art.22047","article-title":"Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications","volume":"54","author":"Cipriani","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0450","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/ard.2008.098277","article-title":"Association between a stromal cell-derived factor 1 (SDF-1\/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis","volume":"68","author":"Manetti","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2024.103514_bb0455","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3389\/fphys.2011.00120","article-title":"Caveolae, caveolins, cavins, and endothelial cell function: new insights","volume":"2","author":"Sowa","year":"2012","journal-title":"Front Physiol"},{"key":"10.1016\/j.autrev.2024.103514_bb0460","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.freeradbiomed.2014.04.029","article-title":"Caveolin-1 is a negative regulator of NADPH oxidase-derived reactive oxygen species","volume":"73","author":"Chen","year":"2014","journal-title":"Free Radic Biol Med"},{"issue":"7","key":"10.1016\/j.autrev.2024.103514_bb0465","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1172\/JCI33338","article-title":"Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration","volume":"119","author":"Zhao","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2024.103514_bb0470","article-title":"Serum Caveolin-1 as a novel biomarker in idiopathic pulmonary artery hypertension","volume":"2015","author":"Wang","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2024.103514_bb0475","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1755-1536-7-13","article-title":"Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis","volume":"7","author":"Cipriani","year":"2014","journal-title":"Fibrogenesis Tissue Repair"},{"issue":"146","key":"10.1016\/j.autrev.2024.103514_bb0480","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0094-2017","article-title":"Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice","volume":"26","author":"Chan","year":"2017","journal-title":"Eur Respir Rev"},{"issue":"413","key":"10.1016\/j.autrev.2024.103514_bb0485","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao4583","article-title":"Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients","volume":"9","author":"Michelakis","year":"2017","journal-title":"Sci Transl Med"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0490","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.ajpath.2016.05.016","article-title":"Increased pyruvate dehydrogenase kinase 4 expression in lung Pericytes is associated with reduced endothelial-Pericyte interactions and small vessel loss in pulmonary arterial hypertension","volume":"186","author":"Yuan","year":"2016","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.autrev.2024.103514_bb0495","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.cmet.2014.08.011","article-title":"Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans","volume":"20","author":"Paulin","year":"2014","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0500","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2004-07-2958","article-title":"Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1","volume":"105","author":"Manalo","year":"2005","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0505","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1038\/cdd.2008.12","article-title":"Biology of HIF-1alpha","volume":"15","author":"Weidemann","year":"2008","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0510","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S0002-9440(10)61705-1","article-title":"Plexiform lesion in severe pulmonary hypertension: association with glomeruloid lesion","volume":"159","author":"Tuder","year":"2001","journal-title":"Am J Pathol"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0515","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.2353\/ajpath.2010.090832","article-title":"Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells","volume":"176","author":"Fijalkowska","year":"2010","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0520","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1183\/09031936.06.00152705","article-title":"Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension","volume":"28","author":"Tamby","year":"2006","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0525","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1183\/09031936.00164209","article-title":"Prevalence of anti-endothelial cell antibodies in idiopathic pulmonary arterial hypertension","volume":"35","author":"Arends","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.autrev.2024.103514_bb0530","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/978-3-030-63046-1_15","article-title":"Cytokines, chemokines, and inflammation in pulmonary arterial hypertension","volume":"1303","author":"Liang","year":"2021","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0535","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/rccm.202108-1919OC","article-title":"Autoimmunity is a significant feature of idiopathic pulmonary arterial hypertension","volume":"206","author":"Jones","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0540","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-3083.2006.01770.x","article-title":"Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension","volume":"64","author":"Vegh","year":"2006","journal-title":"Scand J Immunol"},{"issue":"7","key":"10.1016\/j.autrev.2024.103514_bb0545","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1164\/rccm.201403-0442OC","article-title":"Vascular receptor autoantibodies in pulmonary arterial hypertension associated with systemic sclerosis","volume":"190","author":"Becker","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0550","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1002\/art.39212","article-title":"Anti-endothelin receptor type a autoantibodies in systemic lupus erythematosus-associated pulmonary arterial hypertension","volume":"67","author":"Guo","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2024.103514_bb0555","first-page":"75","article-title":"Agonistic anti-PDGF receptor autoantibodies from patients with systemic sclerosis impact human pulmonary artery smooth muscle cells function in vitro","volume":"8","author":"Svegliati","year":"2017","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0560","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1183\/09031936.00181410","article-title":"Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma","volume":"39","author":"Dib","year":"2012","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0565","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/thx.2004.029082","article-title":"Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension","volume":"60","author":"Tamby","year":"2005","journal-title":"Thorax"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0570","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/cei.12166","article-title":"Immunoglobulin G anti-endothelial cell antibodies: inducers of endothelial cell apoptosis in pulmonary arterial hypertension?","volume":"174","author":"Arends","year":"2013","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2024.103514_bb0575","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2332\/allergolint.11-RAI-0337","article-title":"A histopathological study of pulmonary hypertension in connective tissue disease","volume":"60","author":"Sasaki","year":"2011","journal-title":"Allergol Int"},{"issue":"5","key":"10.1016\/j.autrev.2024.103514_bb0580","first-page":"497","article-title":"Anti-endothelial cell antibodies in connective tissue diseases associated with pulmonary arterial hypertension","volume":"6","author":"Liu","year":"2014","journal-title":"J Thorac Dis"},{"issue":"12","key":"10.1016\/j.autrev.2024.103514_bb0585","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202100851RR","article-title":"The LPS induced pyroptosis exacerbates BMPR2 signaling deficiency to potentiate SLE-PAH","volume":"35","author":"Xing","year":"2021","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.autrev.2024.103514_bb0590","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.2010.135772","article-title":"Involvement of functional autoantibodies against vascular receptors in systemic sclerosis","volume":"70","author":"Riemekasten","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0595","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar4503","article-title":"Angiotensin receptor type 1 and endothelin receptor type a on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patients","volume":"16","author":"Gunther","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0600","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar4457","article-title":"Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis","volume":"16","author":"Kill","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2024.103514_bb0605","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.895501","article-title":"Endothelin B receptor Immunodynamics in pulmonary arterial hypertension","volume":"13","author":"Tabeling","year":"2022","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0610","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1002\/art.20515","article-title":"Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis","volume":"50","author":"H\u00e9nault","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0615","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/cei\/uxad012","article-title":"Systemic sclerosis and primary biliary cholangitis share an antibody population with identical specificity","volume":"212","author":"Favoino","year":"2023","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0620","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1164\/rccm.200707-1015OC","article-title":"Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension","volume":"177","author":"Terrier","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.autrev.2024.103514_bb0625","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/art.10361","article-title":"Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis","volume":"46","author":"Chizzolini","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.autrev.2024.103514_bb0630","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/rheumatology\/kem241","article-title":"Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts","volume":"46","author":"Fineschi","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0635","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.autrev.2015.10.001","article-title":"Anti-centromere protein a antibodies in systemic sclerosis: significance and origin","volume":"15","author":"Perosa","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"25","key":"10.1016\/j.autrev.2024.103514_bb0640","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003931","article-title":"Subspecificities of anticentromeric protein a antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease","volume":"95","author":"Perosa","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102602","article-title":"Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc)","volume":"19","author":"Jiang","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0650","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2397198319870667","article-title":"Pathogenic roles of autoantibodies in systemic sclerosis: current understandings in pathogenesis","volume":"5","author":"Sen\u00e9cal","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"issue":"12","key":"10.1016\/j.autrev.2024.103514_bb0655","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/art.41814","article-title":"Anticentromere antibody levels and isotypes and the development of systemic sclerosis","volume":"73","author":"van Leeuwen","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0660","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/art.42159","article-title":"Criteria for the pathogenicity of anticentromere (anti-CENP-B) autoantibodies in systemic sclerosis: comment on the article by van Leeuwen et al","volume":"74","author":"Sen\u00e9cal","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.autrev.2024.103514_bb0665","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1002\/art.24765","article-title":"Nuclear autoantigen CENP-B transactivation of the epidermal growth factor receptor via chemokine receptor 3 in vascular smooth muscle cells","volume":"60","author":"Robitaille","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0670","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3899\/jrheum.110167","article-title":"Primary biliary cirrhosis-related autoantibodies in a large cohort of italian patients with systemic sclerosis","volume":"38","author":"Cavazzana","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.09.013","article-title":"Ethnic influence on the phenotype of French patients with systemic sclerosis","volume":"88","author":"Steelandt","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2024.103514_bb0680","article-title":"Prevalence and characteristics of systemic sclerosis patients fulfilling the 2019 EULAR\/ACR classification criteria for systemic lupus erythematosus","author":"Bass","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.autrev.2024.103514_bb0685","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00296-018-4059-4","article-title":"The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease","volume":"38","author":"Dima","year":"2018","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0690","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000002761","article-title":"Baseline characteristics and risk factors of pulmonary arterial hypertension in systemic lupus erythematosus patients","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.autrev.2024.103514_bb0695","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/1756-185X.13478","article-title":"Pulmonary arterial hypertension in systemic lupus erythematosus based on a CSTAR-PAH study: baseline characteristics and risk factors","volume":"22","author":"Zhang","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0700","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1017\/S1047951121000688","article-title":"Risk factors of pulmonary arterial hypertension in patients with systemic lupus erythematosus","volume":"31","author":"Lei","year":"2021","journal-title":"Cardiol Young"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0705","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780370111","article-title":"Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0710","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/s10165-011-0515-7","article-title":"Clinical features of 405 Japanese patients with systemic sclerosis","volume":"22","author":"Hashimoto","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0715","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12010013","article-title":"The role of anti-U1 RNP antibody in connective tissue disease-associated pulmonary arterial hypertension: a systematic review and Meta-analysis","volume":"12","author":"Xiang","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.autrev.2024.103514_bb0720","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2249.1999.00864.x","article-title":"Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein","volume":"116","author":"Okawa-Takatsuji","year":"1999","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2024.103514_bb0725","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2249.2001.01669.x","article-title":"Endothelial cell-binding activity of anti-U1-ribonucleoprotein antibodies in patients with connective tissue diseases","volume":"126","author":"Okawa-Takatsuji","year":"2001","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"10.1016\/j.autrev.2024.103514_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/genes11101158","article-title":"Customized massive parallel sequencing panel for diagnosis of pulmonary arterial hypertension","volume":"11","author":"Casta\u00f1o","year":"2020","journal-title":"Genes (Basel)"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997224000016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T17:24:18Z","timestamp":1715361858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997224000016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":146,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1568997224000016"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103514","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idiopathic and connective tissue disease-associated pulmonary arterial hypertension (PAH): Similarities, differences and the role of autoimmunity","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2024.103514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103514"}}